Polypeptide agonists for human interleukin-8

• US 5,877,276 A
• Filed: 04/28/1997
• Issued: 03/02/1999
• Est. Priority Date: 09/23/1994
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Nebraska
• Original Assignee: Board of Regents of the University of Nebraska
• Inventors: Talmadge, James E.
• Primary Examiner(s): Russel, Jeffrey E.
• Application Number:
  US08/847,696
• Time in Patent Office: 673 Days
• Field of Search: 530/324, 530/325, 530/326, 530/327, 514/12, 514/13, 514/14, 930/140, 930/141, 424/85.1, 424/85.2
• US Class Current: 530/324
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/5421 IL-8
• CPC Class Codes: Y10S 930/141 Interleukin

Abstract

Polypeptides derived from human interleukin-8 (IL-8) which act as therapeutic agents for the therapy of neoplastic (both solid and leukemic) and infectious diseases such as bacterial, fungal, viral and parasitic.

Claims

1. A peptide of up to 27 amino acids in length, having agonistic activity for alpha chemokines, said peptide comprising an amino acid sequence having the formula:

Glu-Leu-Arg-Cys-Xaa₁ -Cys-Xaa₂ -Xaa₃ -Xaa₄ -Xaa₅ -Xaa₆ -Xaa₇ -Xaa₈ -Xaa₉ -Xaa ₁₀ -Xaa₁₁ -Xaa₁₂ (SEQ ID NO;

12)

wherein

Xaa₁ is Gln, Met, Leu, Thr, or Val;

Xaa₂ is Ile, Leu, or Val;

Xaa₃ is Lys, Gln, or Ser;

Xaa₄ is Thr, or Ile;

Xaa₅ is Tyr, Leu, Met, His, Val, Asn, or Thr;

Xaa₆ is Ser, Gln, Thr, Leu, Met, Val or Ala;

Xaa₇ is Lys, Arg, Gly, or His;

Xaa₈ is absent or is Pro, Phe, Ile, Val, His, or Gly;

Xaa₉ is absent or is Phe, Ile, Gly, or Val;

Xaa₁₀ is absent or is His, Lys, or Arg;

Xaa₁₁ is absent or is Pro, Leu, or Phe;

Xaa₁₂ is absent or is Lys, His or Arg; and

wherein the amino acid residue Glu in said formula forms the amino terminus of the peptide and at least one Cys residue in said peptide is optionally substituted by an amino acid selected from the group consisting of diaminosuberic acid, homocysteine, or aminobutyric acid.